Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing

Hepatitis C Clinical Trial

Official title:

Clinical Trial Comparing Two Types of Blood Samples (Plasma and SMARTplasma) for HIV and HCV Antibody Testing

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01447680
• Other study ID #: ST-2011-HIV, Version 4
• Status: Completed
• Phase: N/A
• First received: September 22, 2011
• Last updated: September 4, 2015
• Start date: August 2011
• Est. completion date: December 2012

Study information

• Verified date: September 2015
• Source: G & W Laboratories Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUnited States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to compare the results for HIV and/or Hepatitis C Virus antibody testing when using routine plasma versus SMARTplasma from the same blood sample. SMARTplasma is enriched for antibodies via a stimulation step of whole blood in a SMARTube™ (SMARTstim™ in the USA).

Description:

Following exposure to HIV and HCV, there is a "window period" where a person is infected with the virus but does not produce antibodies at a high enough level so they can be detected by antibody detection test methods. During this time, the person is capable of unknowingly transmitting the virus to others. SMARTstim (SMARTube)is a blood sample additive which pre-treats blood, stimulating antibody production in vitro so as to bring it to detectable levels using ELISA (or any other antibody test method). Accelerated antibody production allows antibody detection in specimens that would otherwise be below the detectable limit of antibody test kits. Plasma samples from blood pretreated with SMARTstim are referred to as "SMARTplasma".

A total of 1,600 blood samples will be collected and tested using an ELISA for HIV and HCV using FDA-approved test kits. The populations include:

• 1000 samples from low risk individuals (blood donors) from 3 geographical locations

• 500 samples from high risk individuals at risk for HIV from 2 geographical locations

• 100 known HIV seropositives

This is a non-linked study; that is, no subject identifiers will be associated with the collected blood. Subjects will not receive any correspondences and will not receive any test results.

If discordant results occur between the plasma and SMARTplasma samples, those samples will be retested. A Western Blot will be performed on ELISA repeat reactive discordant samples. HCV testing using an FDA-approved assay may also be performed using retained samples.

Simple statistical methods will be performed as necessary to analyze concordance of results between the sample types in the same ELISA assay.

Secondarily, it is expected that within the scope of this study, it will be shown that:

• Using SMARTplasma does not adversely affect diagnostic specificity of the HIV and/or HCV antibody assay used; i.e., no increase in the rate of HIV or HCV false positive results.

• Using SMARTplasma does not adversely affect diagnostic sensitivity of the HIV and/or HCV antibody assay used; i.e., no decrease in the number of true positive samples.

• Samples from persons with early or acute infection may show a positive result when using SMARTplasma, while those from plasma will test negative.

• SMARTplasma samples using heparin or EDTA collection tubes and the correlating SMARTstim are comparable.

• SMARTplasma samples that have been frozen show comparable results to correlating SMARTplasma samples that have been refrigerated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1600
• Est. completion date: December 2012
• Est. primary completion date: December 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Adults ages 18-64,

• Are not pregnant

• Not have a life-threatening disease

• Not immunosuppressed (HIV therapy allowed)

• Are able to give consent, and (6) who appear healthy.

Exclusion Criteria:

• Do not meet the inclusion criteria

• Are enrolled in an HIV vaccine study,

• Who have previously been enrolled in this study

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• Hepatitis
• Hepatitis C
• HIV Infections
• Human Immunodeficiency Virus Infection
• Immunologic Deficiency Syndromes
• Virus Diseases

Locations

Country	Name	City	State
United States	Evelyn Jordan Center	Baltimore	Maryland
United States	Man Alive, Inc.	Baltimore	Maryland
United States	Reach (Ibr)	Baltimore	Maryland
United States	University of Maryland, School of Medicine	Baltimore	Maryland
United States	American Red Cross	Douglasville	Georgia
United States	Therafirst Medical Centers	Fort Lauderdale	Florida
United States	Bellevue Hospital	New York	New York

Sponsors (3)

Lead Sponsor	Collaborator
G & W Laboratories Inc.	Alquest, SMART Biotech Ltd

Country where clinical trial is conducted

United States, 

References & Publications (3)

Mumo J, Vansover A, Jehuda-Cohen T. Detecting seronegative-early HIV infections among adult versus student Kenyan blood donors, by using Stimmunology. Exp Biol Med (Maywood). 2009 Aug;234(8):931-9. doi: 10.3181/0812-RM-372. Epub 2009 Jun 2. — View Citation

Novikov I, Jehuda-Cohen T. HIV type 1 infection among Ethiopian immigrants to Israel: enhanced in vitro antibody stimulation for estimating the length of the window period. AIDS Res Hum Retroviruses. 2009 Feb;25(2):165-74. doi: 10.1089/aid.2008.0151. — View Citation

Pilcher CD, Tien HC, Eron JJ Jr, Vernazza PL, Leu SY, Stewart PW, Goh LE, Cohen MS; Quest Study; Duke-UNC-Emory Acute HIV Consortium. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis. 2004 May 15;189(10):1785-92. Epub 2004 Apr 28. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concordance of positive and negative results between normal and treated plasma samples when both are tested with the same HIV and/or HCV Enzyme Linked Immunosorbant Assay (ELISA)	There is one timepoint (day 1)for which the primary outcome measure will be assessed and data will be presented. Samples will be collected, delinked and shipped to core lab within 1 day of collection where samples will be processed and subsequently analyzed for HIV and HCV antibodies. Samples will be frozen and retained for future testing. Results of all testing of correlating SMARTplasma and normal plasma samples will be reported as either positive or negative and these results will be compared for concordance.	Blood samples for HIV and HCV testing will be collected at time of consent (day 1).	No
Secondary	Sensitivity and specificity of HIV and HCV antibody assays when used with SMARTplasma	Testing to demonstrate that SMARTplasma does not adversely affect diagnostic specificity & sensitivity of the HIV or HCV antibody assay used (no increase in rate of false positives or false negatives); however,samples from persons with early or acute infection may show a positive result when tested with SMARTplasma while those from normal plasma will test negative. Results of all testing of correlating SMARTplasma and plasma samples will be reported as either positive or negative and these results will be compared for concordance.	Blood samples for HIV and HCV testing will be collected at time of consent (day 1).	No
Secondary	Correlation of results from two different sample types (heparin vs EDTA)	Testing will determine if SMARTplasma samples from collections in heparin or ethylenediaminetetraacetic acid (EDTA) tubes and the correlating SMARTstim sample results are comparable. Results of all testing of correlating heparin and EDTA samples will be reported as either positive or negative and these results will be compared for concordance.	Blood samples for HIV and HCV testing will be collected at time of consent (day 1).	No
Secondary	Correlation of results from refrigerated versus frozen then thawed samples	Following testing for HIV and HCV antibodies (primary outcome measure), an aliquot of each SMARTplasma test samples will be frozen, thawed and retested for HIV and HCV antibodies side-by-side with a corresponding fresh/refrigerated (non-frozen and thawed) sample. Testing will determine if SMARTplasma samples that have been frozen and thawed prior to testing show comparable results to correlating SMARTplasma samples that have been refrigerated. Results will be reported as either positive or negative and these results will be compared for concordance.	Blood samples for HIV and HCV testing will be collected at time of consent (day 1).	No